<DOC>
	<DOCNO>NCT00225914</DOCNO>
	<brief_summary>To evaluate efficacy , safety , tolerability Paroxetine treatment perimenopausal postmenopausal woman present menopause-related symptom discontinue hormone therapy ( HT ) , presence absence concomitant symptom depression anxiety .</brief_summary>
	<brief_title>Study Paxil Use Menopausal Women</brief_title>
	<detailed_description>This study 10-week double-blinded treatment study perimenopausal postmenopausal woman present menopause-related symptom discontinue Hormone Therapy ( HT ) , without concomitant symptom depression anxiety . The menopausal transition period heighten vulnerability mood anxiety disturbance . It also period woman may experience significant vasomotor symptom ( i.e . hot flush night sweat ) . More recently , occurrence vasomotor symptom associate increase risk depression menopausal woman . The efficacy estrogens treatment vasomotor symptom well establish . In addition , literature support modulatory effect exert estrogen various neurotransmitter system regulate mood anxiety . Despite efficacy hormone therapy ( HT ) treatment menopause-related symptom , significant number woman discontinue use first year treatment . Moreover , recent finding Women 's Health Initiative Study ( WHI ) challenge safety benefit initially think associate long-term use HT . As result , many woman take HT decide discontinue use HT , may result significant change physical well , quality life , possibly , mental health status . Therefore , efficacy tolerability intervention antidepressants sub-populations warrant investigation . Treatment Paroxetine show efficacious menopause-related vasomotor symptom . To date , study examine extent SSRIs may improve physical psychological symptom woman discontinue HT .</detailed_description>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>1 . Women age 40 . 2 . Perimenopausal status ( define cycle vary 7 day normal , 2 skip cycle amenorrheic interval least 60 day 12 consecutive month ) postmenopausal status ( define amenorrheic 12 consecutive month ) . 3 . Women prior use HT least two month . 4 . Women discontinue HT use 1 12 month prior study entry ( screen visit ) . 5 . Women present significant menopauserelated symptom ( define GCS total score &gt; 20 ; vasomotor subscores &gt; 3 and/or Â³14 moderate severe hot flash per week ) , without concomitant psychological complaint ( symptom depression and/or anxiety ) . 6 . Women report physical/emotional symptom develop worsen within 3 month HT discontinuation . 7 . General good health . 1 . Women present moderatetosevere symptom depression ( MADRS score &gt; 19 ) anxiety ( BAI score &gt; 19 ) baseline . 2 . Women meet diagnostic criterion screen visit current major Axis I psychiatric disorder specific phobia ( assessed M.I.N.I . interview ) . Subjects present symptom anxiety depression , meet criterion Depressive Disorders , Bipolar Disorder , Panic Disorder , GAD , OCD SAD , allow study . 3 . Regular treatment hormonal medication , SSRIs , tricyclic antidepressant , mood stabilizer , oral neuroleptic , sedative hypnotic , overthecounter agent know influence hot flush mood within 4 week prior screen visit ; use depot neuroleptic within 12 week prior screen visit . 4 . Suicidal ideation , homicidal ideation , psychotic symptom . 5 . Menstrual dysfunction amenorrhea etiology . 6 . History seizure disorder 7 . Pregnancy breastfeeding .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Menopause</keyword>
	<keyword>Hormone Therapy</keyword>
	<keyword>Paxil</keyword>
	<keyword>Hot Flash</keyword>
	<keyword>Sleep Disturbance</keyword>
	<keyword>Night Sweats</keyword>
	<keyword>Antidepressants</keyword>
</DOC>